glp 1 receptor agonists and kidney protection GLP1 vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Kidney Outcomes With Glucagon-Like Peptide-1

Description

Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited by the requirement for injection

GLP-1 is a peptide hormone secreted by L cells in the ileum and colon

GLP-1 drugs like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and orforglipron (Foundayo) offer promising results for weight loss and health.

GLP-1 and its synthetic analogs have emerged as significant therapeutic agents for the management of metabolic disorders, merging glycemic control with weight loss through innovative structural and delivery breakthroughs

### Funding Statement SDL and AC were supported by the National Science Foundation (Grant Nos.\ CAREER DMS-1944574 and DMS-2325258) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained